At the recent British Healthcare Trades Association (BHTA) Conference 2024, Fiona Hilton, Director of Commercial Best Practice & Engagement for NHS England, discussed The Procurement Act 2023 and the Strategic Framework for NHS Commercial.  

The BHTA Conference 2024 focused on the UK healthtech landscape over the next five years. It was a chance for BHTA members to hear from senior government and NHS speakers about how the changes made today will impact the future of the health service.

Fiona highlighted the NHS Commercial portfolio and how it all links together. This revolves around four central initiatives: the NHS Central Commercial Function (CCF) service offers, the Commercial Efficiencies Programme, the Procurement Act, and the Strategic Framework for NHS Commercial. See the slide below for further details.

“We’re trying to link the NHS much more into how the whole of central commercial government works, so that we can collaborate and engage with some of the standard practices that are already in place,” Fiona said.

One key point from Fiona’s presentation is that healthcare procurement is set to transform in 2024 with the introduction of two new procurement regimes: the Procurement Act 2023 and the Provider Selection Regime (PSR).

Fiona emphasised that the NHS believes that the Procurement Act 2023 is key to transforming procurement in the medtech sector. The Act will go live on 28 October 2024.

“We believe that the Procurement Act is a fundamental catalyst to enable change,” added Fiona. “It’s really key for us to be able to establish what we want to do on innovation, working with SMEs, and enabling greater transparency with our suppliers.”

The Procurement Act 2023, she said, will introduce a new competitive and flexible procedure that will enable the NHS to work innovatively and faster with suppliers. It simplifies the regulations that govern public procurement and promises increased commercial flexibility.

Additionally, within the Act, the Competitive Flexible Procedure will allow contracting authorities to design processes that best suit their needs, rather than follow suboptimal standardised procedures.

Importantly, Fiona stressed that the Act will give the NHS an enhanced to take into account poor performance suppliers and the potential debarment of those that do not improve, which will help the NHS improve outcomes.

Additionally, Fiona encouraged medtech suppliers to become familiar with the PSR, which launched in January 2024. It represents a new set of rules governing healthcare services in England. The PSR exempts healthcare contracts from the formal public procurement regime. Fiona added that the regime enables a more flexible, proportionate process when awarding healthcare contracts.

Another important topic from the presentation was around the Strategic Framework for NHS Commercial, which aims to be globally renowned, supporting the delivery of the world-class Commercial Function in healthcare, in patient care, and in outcomes. See the slide below for more information.

Fiona explained: “The Strategic Framework was put together originally in order to be able to support the whole of commercial healthcare for outcomes, not just about value for money upfront. It was about benefitting the whole of the life cycle, and the outcomes across all of commercial.”

The British Healthcare Trades Association (BHTA) recently hosted another successful conference that brought together healthcare leaders and suppliers to discuss how the changes made today will impact the future of the health service.

The sellout BHTA Conference 2024, ‘Health Tech in the UK: The next 5 years’, took place at the Northampton Town Centre Hotel on 21 May and was sponsored by Verlingue.

Boasting an impressive roster of key government and NHS speakers, engaging presentations throughout the day included topics on the MedTech Strategy one year on, the Procurement Act 2023, late-stage medical device assessments, practical export support for UK SMEs, UK medical device regulation changes, and much more.

Attendees had the chance to ask the speakers important questions during two Q&A panel discussions throughout the day.

The conference kicked off with a welcome from BHTA CEO David Stockdale, who highlighted some of the BHTA’s successful campaigns, how the BHTA lobbies to government to ensure its members’ voices are heard, and an overview of the BHTA Conference 2024.

Next, Lord Markham, Parliamentary Under-Secretary from the Department of Health and Social Care (DHSC), shared his opening remarks. Lord Markham outlined that the UK has massive potential to transform the medtech landscape over the next five years and highlighted relevant and successful government initiatives like Innovative Devices Access Pathway (IDAP), the MedTech Strategy, and late-stage medtech assessments.

David Lawson, Director of MedTech for DHSC, delivered a presentation titled ‘Value Not Cost’. He discussed the ‘The medical technology strategy: one year on’ report, the issues DHSC is trying to solve when it comes to the medtech sector, and value-based procurement.  

Fiona Hilton, Director of Commercial Best Practice & Engagement for NHS England, discussed the Strategic Framework for NHS Commercial. Her presentation delved into how the Procurement Act 2023 will significantly change how the NHS works with suppliers and the Strategic Framework for NHS Commercial.

Andrew New, CEO of NHS Supply Chain, presented ‘One Year On – More to Come’. He talked about how NHS Supply Chain will change over the next five years to make it better to work with, and how it aims to enable an optimised, resilient, and sustainable supply chain.

Mark Chapman, Interim Director Medical Technology Digital & Diagnostics at NICE, commenced the afternoon presentations. His presentation was titled ‘NICE HealthTech Assessment: Focus on What Matters Most’. Mark explained the NICE HealthTech Assessment lifecycle approach and late-stage medical device assessments.  

Barney Willis, Deputy Head of Life Sciences for the Department for Business and Trade (DBT), explained how DBT provides practical support to UK medtech SMEs with exporting. Barney provided an insight into how DBT promotes innovative UK medtech companies in key global export markets.

Before the closing remarks, Laura Squire, Chief Healthcare Quality & Access Officer at Medicines and Healthcare products Regulatory Agency (MHRA), delivered the final BHTA Conference 2024 presentation. Her talk, ‘How Regulation of Medical Devices in the UK is Changing’ explored where UK medical device regulation is at now and what the future looks like, alongside international recognition of medical devices.

Positive feedback from the day included:

“An excellent set of speakers and some thought-provoking questions. Given the make-up of BHTA membership, it was good to see several references to the importance of SME business from the speakers.”

“A very good event with really good Q&A sessions. The speakers and the topics they covered should have been of real value to members. I always go looking for 3 or 4 golden nuggets at a day like this, and there were several.”

“It was a really informative day, great speakers, content, location, room, and lunch.”

“It was obvious from how well it went that a lot of work has gone into it, so I hope all the team involved are justifiably proud of the day.”